{"pmid":32497287,"title":"Anticardiolipin antibodies and COVID-19 - A Case Report from America.","text":["Anticardiolipin antibodies and COVID-19 - A Case Report from America.","In an effort to unravel the pathological mechanism of COVID-19, several reports and studies have been recently conducted in the frontlines around the world. Some initial clues have been obtained, and among them, the concern for clot formation and the idea of an impaired coagulation has strongly increased. We report a case of pulmonary embolism in a COVID-19 patient who tested positive for anticardiolipin antibodies. This article is protected by copyright. All rights reserved.","J Med Virol","Manrique, Julio Valencia","Ghosh, Kuldeep","Boma, Noella","32497287"],"abstract":["In an effort to unravel the pathological mechanism of COVID-19, several reports and studies have been recently conducted in the frontlines around the world. Some initial clues have been obtained, and among them, the concern for clot formation and the idea of an impaired coagulation has strongly increased. We report a case of pulmonary embolism in a COVID-19 patient who tested positive for anticardiolipin antibodies. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Manrique, Julio Valencia","Ghosh, Kuldeep","Boma, Noella"],"date":"2020-06-05T11:00:00Z","year":2020,"_id":"32497287","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/jmv.26135","keywords":["coronavirus < virus classification","inflammation < immune responses","interleukin < immune responses"],"locations":["America"],"topics":["Case Report"],"weight":1,"_version_":1668712823961681920,"score":9.490897,"similar":[{"pmid":32441787,"title":"A Rare Case of Immune Thrombocytopenic Purpura Secondary to COVID-19.","text":["A Rare Case of Immune Thrombocytopenic Purpura Secondary to COVID-19.","Coronavirus Disease 2019 (COVID-19) is a newly emerging infectious disease caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). After its first occurrence in Wuhan of China from December 2019, COVID-19 rapidly spread around the world. Studies have shown that coagulation dysfunction is one of the important reason causing death of COVID-19 patients and appeared in many patients. However, cases of COVID-19 with immune thrombocytopenic purpura were very rare. Here, a patient with immune thrombocytopenic purpura in Huoshenshan Hospital (Wuhan, China) was reported, whose laboratory data, clinical treatment and hospital outcome was described in this study. Fortunately, immune thrombocytopenic purpura with COVID-19 of the patient was diagnosed and treated in time and cured eventually. This case illustrates the need to be vigilant for complications associated with COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Yang, Yang","Zhao, Jun","Wu, Jian","Teng, Yi","Xia, Xinyi","32441787"],"abstract":["Coronavirus Disease 2019 (COVID-19) is a newly emerging infectious disease caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). After its first occurrence in Wuhan of China from December 2019, COVID-19 rapidly spread around the world. Studies have shown that coagulation dysfunction is one of the important reason causing death of COVID-19 patients and appeared in many patients. However, cases of COVID-19 with immune thrombocytopenic purpura were very rare. Here, a patient with immune thrombocytopenic purpura in Huoshenshan Hospital (Wuhan, China) was reported, whose laboratory data, clinical treatment and hospital outcome was described in this study. Fortunately, immune thrombocytopenic purpura with COVID-19 of the patient was diagnosed and treated in time and cured eventually. This case illustrates the need to be vigilant for complications associated with COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Yang, Yang","Zhao, Jun","Wu, Jian","Teng, Yi","Xia, Xinyi"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32441787","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/jmv.26051","keywords":["coronavirus < virus classification","disease control","immune responses"],"locations":["Wuhan","China","Huoshenshan Hospital","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1667523504786898945,"score":109.083244},{"pmid":32379918,"title":"Coagulopathy of COVID-19 and antiphospholipid antibodies.","text":["Coagulopathy of COVID-19 and antiphospholipid antibodies.","Recently in the Journal of Thrombosis and Haemostasis, Harzallah and colleagues report the results of antiphospholipid antibody testing in a series of 56 patients with confirmed or suspected SARS-CoV-2 infection.[1] Twenty-five patients were found to be positive for lupus anticoagulants, while five patients had either anticardiolipin or anti-beta2-glycoprotein I antibodies. The isotypes for the anticardiolipin and anti-beta2-glycoprotein I antibodies were reportedly IgG and IgM, although specific antibody titers and details of which were found in combination with a lupus anticoagulant in three overlap patients were not reported.","J Thromb Haemost","Connell, Nathan T","Battinelli, Elisabeth M","Connors, Jean M","32379918"],"abstract":["Recently in the Journal of Thrombosis and Haemostasis, Harzallah and colleagues report the results of antiphospholipid antibody testing in a series of 56 patients with confirmed or suspected SARS-CoV-2 infection.[1] Twenty-five patients were found to be positive for lupus anticoagulants, while five patients had either anticardiolipin or anti-beta2-glycoprotein I antibodies. The isotypes for the anticardiolipin and anti-beta2-glycoprotein I antibodies were reportedly IgG and IgM, although specific antibody titers and details of which were found in combination with a lupus anticoagulant in three overlap patients were not reported."],"journal":"J Thromb Haemost","authors":["Connell, Nathan T","Battinelli, Elisabeth M","Connors, Jean M"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32379918","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/jth.14893","topics":["Diagnosis"],"weight":1,"_version_":1666262687574654978,"score":100.2074},{"pmid":32305287,"pmcid":"PMC7162739","title":"Severe Acute Proximal Pulmonary Embolism and COVID-19: A Word of Caution.","text":["Severe Acute Proximal Pulmonary Embolism and COVID-19: A Word of Caution.","Acute pulmonary embolism is an uncharacteristic presentation in patients with COVID-19. Here we describe the case of a young woman presenting with severe pulmonary embolism, without any associated symptoms of infections. A clot in a patent foramen ovale was noted. Despite emergency surgical embolectomy, her clinical conditions continued to deteriorate. She was put on extracorporeal life support and tested positive for COVID-19. She died of multiorgan failure on day 10. COVID-19 may have a thrombogenic effect and it may need to be considered in cases of pulmonary embolism and in absence of any obvious risk factor.","Ann Thorac Surg","Fabre, Olivier","Rebet, Olivier","Carjaliu, Ionut","Radutoiu, Mihai","Gautier, Laurence","Hysi, Ilir","32305287"],"abstract":["Acute pulmonary embolism is an uncharacteristic presentation in patients with COVID-19. Here we describe the case of a young woman presenting with severe pulmonary embolism, without any associated symptoms of infections. A clot in a patent foramen ovale was noted. Despite emergency surgical embolectomy, her clinical conditions continued to deteriorate. She was put on extracorporeal life support and tested positive for COVID-19. She died of multiorgan failure on day 10. COVID-19 may have a thrombogenic effect and it may need to be considered in cases of pulmonary embolism and in absence of any obvious risk factor."],"journal":"Ann Thorac Surg","authors":["Fabre, Olivier","Rebet, Olivier","Carjaliu, Ionut","Radutoiu, Mihai","Gautier, Laurence","Hysi, Ilir"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32305287","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.athoracsur.2020.04.005","locations":["multiorgan"],"topics":["Case Report"],"weight":1,"_version_":1666138493385965568,"score":93.43282},{"pmid":32369214,"title":"Letter to the Editor: Three cases of re-detectable positive SARS-CoV-2 RNA in recovered COVID-19 patients with antibodies.","text":["Letter to the Editor: Three cases of re-detectable positive SARS-CoV-2 RNA in recovered COVID-19 patients with antibodies.","The number of hospitalized cases has declined significantly in Wuhan. However, there have been reports that several cases of re-detectable positive SARS-CoV-2 RNA in recovered COVID-19 patients, the potential reasons of re-detectable positive patients remained elusive. Here, we report three confirmed cases of COVID-19 whose IgM was negative and IgG was positive before the first discharge, while nasopharyngeal swab test of SARS-CoV-2 RNA turned positive again during hotel isolation. In addition, all three cases presented negative results for IgM antibodies and positive results for IgG antibodies during re-admission period. These cases suggested that the reasons for re-detectable positive patients with profile of antibodies may be related to several factors. It is necessary to quarantine COVID-19 patients for 14 days after discharge, and the role of antibodies in anti-SARS-CoV-2 warrants further investigation. This article is protected by copyright. All rights reserved.","J Med Virol","Fu, Wei","Chen, Qian","Wang, Tao","32369214"],"abstract":["The number of hospitalized cases has declined significantly in Wuhan. However, there have been reports that several cases of re-detectable positive SARS-CoV-2 RNA in recovered COVID-19 patients, the potential reasons of re-detectable positive patients remained elusive. Here, we report three confirmed cases of COVID-19 whose IgM was negative and IgG was positive before the first discharge, while nasopharyngeal swab test of SARS-CoV-2 RNA turned positive again during hotel isolation. In addition, all three cases presented negative results for IgM antibodies and positive results for IgG antibodies during re-admission period. These cases suggested that the reasons for re-detectable positive patients with profile of antibodies may be related to several factors. It is necessary to quarantine COVID-19 patients for 14 days after discharge, and the role of antibodies in anti-SARS-CoV-2 warrants further investigation. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Fu, Wei","Chen, Qian","Wang, Tao"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32369214","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/jmv.25968","keywords":["antibody","covid-19","rna","sars-cov-2"],"locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1666138496138477570,"score":90.63716},{"pmid":32312574,"pmcid":"PMC7141630","title":"COVID-19 pneumonia with hemoptysis: Acute segmental pulmonary emboli associated with novel coronavirus infection.","text":["COVID-19 pneumonia with hemoptysis: Acute segmental pulmonary emboli associated with novel coronavirus infection.","Recent retrospective studies from Wuhan, China suggest Novel Coronavirus Disease 2019 (COVID-19) may be associated with a hypercoagulable state and increased risk for venous thromboembolism. The overlap in the signs and symptoms of COVID-19 associated Acute Respiratory Distress Syndrome (ARDS) and COVID-19 with concurrent pulmonary embolism creates a diagnostic challenge for emergency medicine physicians in patients already at risk for renal impairment. However, identifying features atypical for COVID-19 alone may play a role in the judicious use of Computed Tomography Angiography among these patients. Hemoptysis is seen in roughly 13% of pulmonary embolism cases and infrequently reported among COVID-19 infections. Additionally, the presence of right heart strain on electrocardiography (EKG) is a well described clinical presentations of pulmonary embolism not reported commonly with COVID-19 infections.","Am J Emerg Med","Casey, Kyla","Iteen, Alexander","Nicolini, Reese","Auten, Jonathan","32312574"],"abstract":["Recent retrospective studies from Wuhan, China suggest Novel Coronavirus Disease 2019 (COVID-19) may be associated with a hypercoagulable state and increased risk for venous thromboembolism. The overlap in the signs and symptoms of COVID-19 associated Acute Respiratory Distress Syndrome (ARDS) and COVID-19 with concurrent pulmonary embolism creates a diagnostic challenge for emergency medicine physicians in patients already at risk for renal impairment. However, identifying features atypical for COVID-19 alone may play a role in the judicious use of Computed Tomography Angiography among these patients. Hemoptysis is seen in roughly 13% of pulmonary embolism cases and infrequently reported among COVID-19 infections. Additionally, the presence of right heart strain on electrocardiography (EKG) is a well described clinical presentations of pulmonary embolism not reported commonly with COVID-19 infections."],"journal":"Am J Emerg Med","authors":["Casey, Kyla","Iteen, Alexander","Nicolini, Reese","Auten, Jonathan"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32312574","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.ajem.2020.04.011","keywords":["covid-19","coronavirus","pulmonary embolism","sars-cov-2","venous thromboembolism"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1666138493425811458,"score":89.117714}]}